Copyright
©The Author(s) 2023.
World J Gastroenterol. Dec 28, 2023; 29(48): 6179-6197
Published online Dec 28, 2023. doi: 10.3748/wjg.v29.i48.6179
Published online Dec 28, 2023. doi: 10.3748/wjg.v29.i48.6179
Stage | |
I | Tumor confined to GI tract |
Primary site or multiple, non-contiguous lesions | |
II | Tumor extends into the abdomen from primary GI site |
Nodal involvement | |
II1 | Local: Paragastric in cases of gastric lymphoma and para-intestinal for intestinal lymphoma |
II2 | Distant: Mesenteric in case of an intestinal primary lymphoma; otherwise paraaortic, paracaval, pelvic, or inguinal |
IIE | Penetration of serosa involving adjacent organs or tissues: Enumerate sites of involvement, e.g., IIE (pancreas), IIE (large intestine), IIE (post-intestinal wall) |
Where there is nodal involvement and penetration involving adjacent organs, the stage is denoted using a subscript (1 or 2) and E, e.g., II1E (pancreas) | |
IV | Disseminated extra-nodal involvement or a GI tract lesion with supradiaphragmatic nodal involvement |
- Citation: Watanabe T. Gene targeted and immune therapies for nodal and gastrointestinal follicular lymphomas. World J Gastroenterol 2023; 29(48): 6179-6197
- URL: https://www.wjgnet.com/1007-9327/full/v29/i48/6179.htm
- DOI: https://dx.doi.org/10.3748/wjg.v29.i48.6179